Most explanations of ketamine therapy are written for people who already want it. This one is for the person who does not, or who has not decided, and who would like the mechanics without the enthusiasm.
The reason to write it is a number. When our poll reached 443 Midwest adults, cautious but open was how 34 percent felt about ketamine or esketamine care, and 18 percent were hopeful or curious. Against that, skeptics were 21 percent and outright negatives 9 percent, while 18 percent had not heard of it. So about half the room leans open, and firm opposition stays under one in ten. The figures are final.
Between those poles sits a large group of people in O'Fallon and everywhere else who would form an opinion if someone explained the thing. Here is the explanation, uncomfortable parts included.
Three different products wear the same name
The first correction does the most work: "ketamine therapy" is not one offering.
Spravato's active ingredient, esketamine, is one mirror-image half of the ketamine molecule, delivered as a nasal spray. Its FDA approval covers depression that has not responded to adequate trials of other antidepressants. It is used only inside a certified clinic under supervision, you are observed after each dose, and you may not drive again until the next day, so arrange a ride. Our respondents barely knew it: 73 percent were unaware of the name, 21 percent had heard the word and no more, and 6 percent could explain it.
Intravenous ketamine at a clinic is generic ketamine, a hospital anesthetic for decades, infused over roughly a lunch break. Such use is off label: legal and ordinary in medicine, yet no regulator has reviewed a marketing claim for this indication. Quality and protocol depend on who runs the clinic.
At-home compounded ketamine comes after a telehealth visit as lozenges or a nasal preparation shipped to you. Nobody is physically with you, and the product comes from a compounding pharmacy, not an approved manufacturer. Of the three, this one is grayest and earns the hardest questions.
What an approved esketamine appointment actually looks like
The structure surprises people who picture a prescription handed across a counter. You take the dose at the clinic and you stay. Staff watch you for a while because blood pressure changes and dissociation, a floaty, disconnected feeling, are expected effects. Then someone else drives. Brain Recovery Centers has a straightforward walk-through of a Spravato visit if you want to see the sequence laid out.
Early appointments are usually clustered, then spaced out if a clinician judges that continuing makes sense. That cadence makes logistics a real question, and it helps explain why 43 percent of our respondents put living close by in their top two provider factors. A treatment that needs a driver and an afternoon is one whose address matters.
The parts nobody puts on a billboard
Dissociation is part of the experience for many people, and some find it unpleasant. Blood pressure can climb during a session, one reason monitoring exists. Ketamine has recognized misuse potential, another reason the approved product stays in supervised settings rather than going home in a bottle.
And it does not work for everyone. No responsible description promises a result, and anything that does, including advertising that sounds like this article, should lose your trust at once.
A clinic that describes only benefits has not explained the treatment. It has described a product.
Why skepticism and demand share the same households
Asked about lived experience, 72 percent of respondents said first-line medication had failed to resolve depression, anxiety, or PTSD for them or someone close. Thirty-seven percent said it was theirs and 22 percent a loved one's; 13 percent said both, and 28 percent neither.
That is the context for every cautious answer. People are not skeptical because things are going well. They are skeptical because something already failed them once, and they would rather not repeat that with a pricier option.
Who decides, and it is not a website
We asked whose recommendation would really get someone to try this. Their own doctor won with 74 percent. Friends and relatives got 18, people in uniform they follow online got 4, ads 2, and podcast hosts 1. For a first stop, the primary doctor was named by 56 percent and a psychiatrist or other mental health clinician by 23; 12 percent would search online, 5 percent were stumped, and 1 percent would ask a friend.
If you are unconvinced, that ordering helps you. The people best placed to judge whether any of this applies are the ones who know your diagnosis and your other medications, and who are not paid more for a yes.
Reasonable things to ask before agreeing to anything
- Which of the three arrangements is this, and is the product FDA-approved for my diagnosis?
- What must be true of my treatment history for me to qualify?
- Who supervises the session, and what happens if my blood pressure rises?
- Will insurance cover it, and can I see that in writing before the first visit?
- What signals would tell us to stop, and how does stopping work?
On coverage the sample was blunt: 65 percent called insurance decisive or a big factor. Offered a covered path with more hoops or a faster one paid out of pocket, 51 percent took the hoops; paying drew 23 percent and uncertainty 26 percent.
What this article is not
It is not medical advice or evidence. It describes how a treatment is structured and reports what a general-population sample said about the idea. Deciding whether esketamine or anything else fits you requires a clinician to examine your history.
Please take one thing out of order. If depression has pushed you toward suicidal thoughts, do not wait until your research is done. Calls and texts to 988 reach the Lifeline around the clock, anywhere in the country, at no cost. Telling someone is the step that makes every other step possible.
Methodology
Everything cited comes from one first-party study, Pollfish panel survey 395586438, which the publisher of this site commissioned and funded. Fieldwork closed June 23, 2026. The sample, n=443, was drawn from the general population of ten Midwest states, ages 18 to 64, with no screening for diagnosis. Where a question allowed several answers, percentages are shares of respondents and add to more than 100. The data come from the panel's completed validation pass, and this article uses top-line percentages only, so no subgroup figures appear here.